ArticleNucleic acids research2026
Topoisomerase III limits RecA-dependent DNA amplification in the chromosome terminus with RecG.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Topoisomerase (topo) III is a ubiquitous type IA enzyme whose role in suppressing inappropriate recombination is well established in eukaryotes but remains poorly defined in prokaryotes. In Escherichia coli, deletion of topB (encoding topo III) in topA mutants (topo I, which normally prevents R-loop formation) leads to pronounced Ter/Tus barrier-dependent DNA amplification in the chromosomal terminus region. In recG mutants, this phenotype was recently attributed to RecA-mediated D-loop formation at DNA double-strand ends (DSEs) generated at Ter/Tus barriers, triggering replication restart in the incorrect orientation (re-replication). Here, our data indicate that, as in recG mutants, RecA drives repeated cycles of Ter/Tus barrier-dependent DSE formation and re-replication, thereby promoting chromosomal terminus DNA amplification in topA topB cells. Deletion of topB enhances Ter/Tus-dependent amplification in rnhA cells but not in recG cells. Moreover, deletion of recG or topB, but not recQ, markedly exacerbates the replication-completion defect of topA mutants, unless recA is deleted or topo IV is overproduced. Together, these findings suggest that topo III and RecG cooperate to restrain RecA-mediated re-replication at sites of DSE formation, thereby preventing pathological DNA amplification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.